Trial Profile

A phase IIb/III clinical trial of AXA1665 in overt Hepatic Encephalopathy

Status: Planning

Phase of Trial: Phase II/III

Latest Information Update: 07 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AXA 1665 (Primary)
Indications Hepatic encephalopathy
Focus Registrational; Therapeutic Use
Sponsors Axcella Health

Most Recent Events

05 Aug 2020 According to an Axcella Health media release, the company plan to initiate this study in 1H 2021.
23 Mar 2020 According to an Axcella Health media release, the company plan to submit an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) in Q4 2020.
08 Jan 2020 According to an Axcella Health media release, IND submission for overt hepatic encephalopathy is planned for second half of 2020.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com